This document lists 63 research publications by Claudio Faravelli and Stefano Pallanti related to mood disorders, panic disorder, obsessive-compulsive disorder, schizophrenia, and other topics. The publications span from 1986 to 2005 and were published in journals such as the American Journal of Psychiatry, Biological Psychiatry, and the Journal of Clinical Psychiatry. Many of the publications report on clinical trials of pharmacological treatments for various conditions.

1. 1. Faravelli C, Sacchetti E, Ambonetti A, Conte G, Pallanti S, Vita A. Recent life events
and affective disorder revisited. British Journal of Psychiatry. 1986 Mar;148:288-95.
2. Faravelli C, Ambonetti A, Pallanti S, Pazzagli A. Depressive relapses and
incomplete recovery from index episode. American Journal of Psychiatry. 1986
Jul;143(7):888-91.
3. Faravelli C, Pallanti S. Clomipramine by different routes of administration: short-
and long-term efficacy and predictors of clinical outcome. Psychopharmacol Bull.
1987;23(3):459-63.
4. Faravelli C, Pallanti S, Frassine R, Albanesi G, Guerrini Degl'Innocenti B. Panic
attacks with and without agoraphobia: a comparison. Psychopathology.
1988;21(1):51-6.
5. Faravelli C, Pallanti S, Strik WK. [Stress load and schizophrenic disorder].
Nervenarzt. 1988 Apr;59(4):237-9. German.
6. Faravelli C, Pallanti S. Recent life events and panic disorder. American Journal of
Psychiatry. 1989 May;146(5):622-6.
7. Smeraldi E, Orsini A, Gasperini M, Sciuto G, Battaglia M, Cassano GB, Perugi G,
Faravelli C, Pallanti S, Bressa G. Familial analysis of panic disorder and
agoraphobia. Journal of Affective Disorders, 1989, vol.17, p.1-8. ISSN: 0165-0327.
8. Faravelli C, Guerrini Degl'Innocenti B, Aiazzi L, Incerpi G, Pallanti S. Epidemiology
of mood disorders: a community survey in Florence. Journal of Affective Disorders.
1990 Oct;20(2):135-41.
9. Faravelli C, Panichi C, Pallanti S, Paterniti S, Grecu LM, Rivelli S. Perception of
early parenting in panic and agoraphobia. Acta Psychiatrica Scandinavica. 1991
Jul;84(1):6-8.
10. Faravelli C, Pallanti S, Biondi F, Paterniti S, Scarpato MA. Onset of panic disorder.
American Journal of Psychiatry. 1992 Jun;149(6):827-8.
11. Pallanti S, Mazzi D. MDMA (Ecstasy) precipitation of panic disorder. Biological
Psychiatry. 1992 Jul 1;32(1):91-5.
12. Zaccara G, Gangemi PF, Muscas GC, Paganini M, Pallanti S, Parigi A, Messori A,
Arnetoli G. Smooth-pursuit eye movements: alterations in Alzheimer's disease.
Journal of the Neurological Science. 1992 Oct;112(1-2):81-9. Volume 112, Issues 1-
2, 1992,
13. Pages 81-89. ISSN 0022-510X. https://doi.org/10.1016/0022-510X(92)90136-9.
(https://www.sciencedirect.com/science/article/pii/0022510X92901369)
14. M.Weissman, L.Bobins, J.Escobar, R.Bland, G.Canino, H.Wittchen, C.Faravelli,
S.Pallanti, J.Lepine, P.Pariente, E.Karam, J.Wells, H.Hwu, G.Klerman, P.Lavori,
W.Maier (1992). The changing rate of depression. JAMA, vol. 268, p. 3098-3105,

2. ISSN: 0098-7484.
15. Pallanti S., Pavia R.S. A demencia emu ma prospectiva psico (pato) lògica.
[Dementia in a psycho(patho)logical perspective] Jornal Brasiliero de Psiquiatria
[Brazilian Journal of Psychiatry] 41 (9), 447-50. Ott. 1992.
16. Faravelli C., Pallanti S., Biondi F., Paterniti S., Scarpato M.A. Assessment of onset
of panic disorder in relatrion to onset of agoraphobia-replay. American Journal of
Psychiatry 150 (9), 1437-1437. 1993-09-01.
17. Pallanti, S. et al. Depth perception in schizophrenia. Biological Psychiatry, Volume
35, Issue 9, 637 - 638 Published in issue: May 01, 1994
18. Mortilla M, Amaducci L, Bruni A, Montesi MP, Trubnikov A, De Cataldo S, Pallanti S,
Pazzagli A, Grecu L, Servi P, et al. Absence of APP713 mutation in Italian and
Russian families with schizophrenia. Neuroscience Letters 1994 Jan 3;165(1-2):45-
7.
19. Grassi E, Mortilla M, Amaducci L, Pallanti S, Pazzagli A, Galassi F, Guarnieri BM,
Petruzzi C, Bolino F, Ortenzi L, Nistico R, De Cataldo S, Rossi A, Sorbi S. No
evidence of linkage between schizophrenia and D2 dopamine receptor gene locus
in Italian pedigrees. Neuroscience Letters 1996 Mar 15;206(2-3):196-8.
20. Pallanti S, Grecu LM, Gangemi PF, Massi S, Parigi A, Arnetoli G, Quercioli L,
Zaccara G. Smooth-pursuit eye movement and saccadic intrusions in obsessive-
compulsive disorder. Biological Psychiatry. 1996 Dec 1;40(11):1164-72.
21. Pallanti S, Koran LM. Two case report. CNS Spectrums 1996, vol.1, p.54-57, ISSN:
1092-8529.
22. Bersani G., Saito A. Pallanti S. Sasso E., Tosca P. Clinical variables and response
to citalopram in Major Depression: an open multicentric study. Rivista di Psichiatria
32, 260-267, 1997.
23. Pallanti S. Personality Disorders: Myths and Neuroscience. CNS Spectrums 2, 53-
63, 1997.
24. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of
clomipramine in obsessive-compulsive disorder. American Journal of Psychiatry.
1997 Mar;154(3):396-401.
25. Pallanti S, Quercioli L, Pazzagli A. Relapse in young paranoid schizophrenic
patients: a prospective study of stressful life events, P300 measures, and coping.
American Journal of Psychiatry. 1997 Jun;154(6):792-8.
26. Ramacciotti A, Pallanti S, Pazzagli A. A setting including psychotherapy and
psychopharmacological treatment in a case of anorexia nervosa with obsessive
compulsive disorder comorbidity. Eating and Weight Disorders. 1997 Dec;2(4):222-
8.

3. 27. Inzitari D, Pantoni L, Lamassa M, Pallanti S, Pracucci G, Marini P. Emotional
arousal and phobia in transient global amnesia. Archives of Neurology. 1997
Jul;54(7):866-73.
28. Pallanti S, Quercioli L, Ramacciotti A. Citalopram in anorexia nervosa. Eating and
Weight Disorders. 1997 Dec;2(4):216-21.
29. Pallanti S, Quercioli L, Zaccara G, Ramacciotti AB, Arnetoli G. Eye movement
abnormalities in anorexia nervosa. Psychiatry Research. 1998 Mar 20;78(1-2):59-
70.
30. Koran LM, Pallanti S, Paiva RS, Quercioli L. Pulse loading versus gradual dosing of
intravenous clomipramine in obsessive-compulsive disorder. Eur
Neuropsychopharmacol. 1998 May;8(2):121-6.
31. Sallee FR, Koran LM, Pallanti S, Carson SW, Sethuraman G. Intravenous
clomipramine challenge in obsessive-compulsive disorder: predicting response to
oral therapy at eight weeks. Biological Psychiatry. 1998 Aug 1;44(3):220-7.
32. Pallanti, S., Quercioli, L. Cognitive subjective disturbances of schizophrenia: Effect
of atypical neuroleptics. European Neuropsychopharmacology, 1999
33. Pallanti S., Quercioli L. Objective and subjective investigation of cognitive deficits in
young schizophrenic patients. Journal of Psychophysiology 13 (3), 203-203, 1999-
01-01.
34. Pallanti S, Koran LM. Citalopram and sexual side effects of selective serotonin
reuptake inhibitors. American Journal of Psychiatry. 1999 May;156(5):796.
10327919.
35. Pallanti S, Quercioli L, Pazzagli A. Effects of clozapine on awareness of illness and
cognition in schizophrenia. Psychiatry Research. 1999 Jun 30;86(3):239-49.
36. Pallanti S, Quercioli L, Pazzagli A, Rossi A, Dell'Osso L, Pini S, Cassano GB.
Awareness of illness and subjective experience of cognitive complaints in patients
with bipolar I and bipolar II disorder. American Journal of Psychiatry. 1999
Jul;156(7):1094-6.
37. Pallanti S, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant
obsessive-compulsive disorder. European Psychiatry. 1999 Apr;14(2):101-6.
38. Pallanti S, Quercioli L, Pazzagli A. Basic symptoms and P300 abnormalities in
young schizophrenic patients. Comprehensive Psychiatry. 1999 Sep-Oct;40(5):363-
71.
39. Pini S, Dell'Osso L, Mastrocinque C, Marcacci G, Papasogli A, Vignoli S, Pallanti S,
Cassano G. Axis I comorbidity in bipolar disorder with psychotic features. British
Journal of Psychiatry 1999.467-71.
40. Pallanti S, Quercioli L, Rossi A, Pazzagli A. The emergence of social phobia during
clozapine treatment and its response to fluoxetine augmentation. Journal of Clinical

4. Psychiatry. 1999 Dec;60(12):819-23.
41. Di Russo F, Zaccara G, Ragazzoni A, Pallanti S. Abnormal visual event-related
potentials in obsessive-compulsive disorder without panic disorder or depression
comorbidity. Journal of Psychiatric Research. 2000 Jan-Feb;34(1):75-82.
42. Pallanti S, Quercioli L. Shame and psychopathology. CNS Spectrums. 2000
Aug;5(8):28-43.
43. Pallanti S, Quercioli L, Pazzagli A. Social anxiety and premorbid personality
disorders in paranoid schizophrenic patients treated with clozapine. CNS
Spectrums. 2000 Sep;5(9):29-43.
44. Rossi A, Arduini L, Stratta P, Pallanti S. Subjective experience and subjective
response to neuroleptics in schizophrenia. Comprehensive Psychiatry. 2000 Nov-
Dec;41(6):446-9.
45. Koran LM, Pallanti S, Quercioli L. Sumatriptan, 5-HT(1D) receptors and obsessive-
compulsive disorder. European Neuropsychopharmacology. 2001 Apr;11(2):169-72.
46. Hollander E., Bienstock C.A., Koran L.M., Pallanti S., Marazzini D., Rasmussen
S.A., Ravizza L., Benkelfat C., saxena S., Greenberg D.B., Sasson Y., Zohar J.
Refractory obsessive-compulsive disorder: state-of-the-art treatment. Journal of
Clinical Psychiatry 63, 20-29, 12-2001.
47. Pallanti S., Quercioli L. Alternative route of administration and titration of SRIs in
anxious resistant patients:Two day-hospital experiences. European
Neuropsychopharmacology 11, S312, 2001-12-31.
48. Ramacciotti A, Sorbello M, Pazzagli A, Vismara L, Mancone A, Pallanti S.
Attachment processes in eating disorders. Eat Weight Disord. 2001 Sep;6(3):166-
70.
49. Presta S, Marazziti D, Dell'Osso L, Pfanner C, Pallanti S, Cassano GB.
Kleptomania: clinical features and comorbidity in an Italian sample. Comprehensive
Psychiatry. 2002 Jan-Feb;43(1):7-12.
50. Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA,
Ravizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, Zohar J. Refractory
obsessive-compulsive disorder: state-of-the-art treatment. Journal of Clinical
Psychiatry. 2002;63 Suppl 6:20-9.
51. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M,
Stein D, Zohar J; International Treatment Refractory OCD Consortium. Treatment
non-response in OCD: methodological issues and operational definitions.
International Journal of Neuropsychopharmacology. 2002 Jun;5(2):181-91.
52. Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of
pathological gambling: a randomized single-blind study. Journal of Clinical
Psychiatry. 2002 Jul;63(7):559-64.

5. 53. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant
obsessive-compulsive disorder: an open trial. Journal of Clinical Psychiatry. 2002
Sep;63(9):796-801.
54. Pallanti S, Baldini Rossi N, Sood E, Hollander E. Nefazodone treatment of
pathological gambling: a prospective open-label controlled trial. Journal of Clinical
Psychiatry. 2002 Nov;63(11):1034-9.
55. Buchsbaum M.S., Hollander E., Pallanti S., Baldini-Rossi N. Brikman A.M., Platholi
J., Sood E. Positron emission tomography. Imaging of risperidone augmentation in
SRI-refractory patients. Biological Psychiatry 51 (8), 47S-47S, 2002-04-14.
56. Pallanti S., Rossi N.B., Friedberg J., Hollander E. Psychobiology of Impulse-Control
Disorders Not Otherwise Specified (NOS). Biological Psychiatry 2003, 1315-1329.
57. Sood ED, Pallanti S, Hollander E. Diagnosis and treatment of pathologic gambling.
Current Psychiatry Reports. 2003 May;5(1):9-15.
58. Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in
treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-
controlled study. International Journal of Neuropsychopharmacology. 2003
Dec;6(4):397-401.
59. Pallanti S, Quercioli L, Hollander E. Social anxiety in outpatients with schizophrenia:
a relevant cause of disability. American Journal of Psychiatry. 2004 Jan;161(1):53-8.
60. Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine
augmentation of citalopram in obsessive-compulsive disorder patients without
comorbid depression: a pilot study. Journal of Clinical Psychiatry. 2004
Oct;65(10):1394-9.
61. Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse:
management of treatment-refractory obsessive-compulsive disorder. Journal of
Clinical Psychiatry. 2004;65 Suppl 14:6-10.
62. Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained-release
lithium reduce impulsive gambling and affective instability versus placebo in
pathological gamblers with bipolar spectrum disorders? American Journal of
Psychiatry. 2005 Jan;162(1):137-45.
63. Hollander E, Sood E, Pallanti S, Baldini-Rossi N, Baker B. Pharmacological
treatments of pathological gambling. Journal of Gambling Studies. 2005
Spring;21(1):99-110.
64. Haznedar MM, Roversi F, Pallanti S, Baldini-Rossi N, Schnur DB, Licalzi EM, Tang
C, Hof PR, Hollander E, Buchsbaum MS. Fronto-thalamo-striatal gray and white
matter volumes and anisotropy of their connections in bipolar spectrum illnesses.
Biological Psychiatry. 2005 Apr 1;57(7):733-42.
65. Urpe M, Pallanti S, Lotti T. Psychosomatic factors in dermatology. Dermatologic
Clinics. 2005 Oct;23(4):601-8.

6. 66. Pallanti S, Lotti T, Urpe M. Psychoneuroimmunodermatology of atopic dermatitis:
from empiric data to the evolutionary hypothesis. Dermatologic Clinics. 2005
Oct;23(4):695-701.
67. Hollander E, Pallanti S, Baldini Rossi N, Sood E, Baker BR, Buchsbaum MS.
Imaging monetary reward in pathological gamblers. World Journal of Biological
Psychiatry. 2005;6(2):113-20.
68. Pallanti S, Lassi S, La Malfa G, Campigli M, Di Rubbo R, Paolini G, Cesarali V.
Short report: Autistic gastrointestinal and eating symptoms treated with secretin: a
subtype of autism. Clinical Practice & Epidemiology in Mental Health. 2005 Nov 15;
1:24.
69. Pallanti S, DeCaria CM, Grant JE, Urpe M, Hollander E. Reliability, and validity of
the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive
Scale (PG-YBOCS). Journal of Gambling Studies. 2005 Winter;21(4):431-43.
70. Rossi A, Rucci P, Mauri M, Maina G, Pieraccini F, Pallanti S, Endicott J; (For the
EQUIP group). Reliability and validity of the Italian version of the Quality of Life,
Enjoyment and Satisfaction Questionnaire. Quality of Life Research. 2005
Dec;14(10):2323-8.
71. Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder:
methodological issues, operational definitions and therapeutic lines. Progress in
Neuro-Psychopharmacology & Biological Psychiatry. 2006 May;30(3):400-12.
72. Pallanti, S. (2006). From Impulse-Control Disorders Toward Behavioral Addictions.
CNS Spectrums. 11. 921-922. 10.1017/S1092852900015108.
73. Buchsbaum MS, Hollander E, Pallanti S, Baldini Rossi N, Platholi J, Newmark R,
Bloom R, Sood E. Positron emission tomography imaging of risperidone
augmentation in serotonin reuptake inhibitor-refractory patients.
Neuropsychobiology. 2006;53(3):157-68.
74. Pallanti S, Bernardi S, Quercioli L, DeCaria C, Hollander E. Serotonin dysfunction in
pathological gamblers: increased prolactin response to oral m-CPP versus placebo.
CNS Spectrums. 2006 Dec;11(12):956-64.
75. Pallanti S, Bernardi S, Quercioli L. The Shorter PROMIS Questionnaire and the
Internet Addiction Scale in the assessment of multiple addictions in a high-school
population: prevalence and related disability. CNS Spectrums. 2006;11(12):966-74.
76. Pallanti S, Quercioli L. Resistant social anxiety disorder response to Escitalopram.
Clinical Practice & Epidemiology in Mental Health. 2006;13; 2:35.
77. Hollander E, Kim S, Khanna S, Pallanti S. Obsessive-compulsive disorder and
obsessive-compulsive spectrum disorders: diagnostic and dimensional issues. CNS
Spectrums. 2007 Feb;12(2 Suppl 3):5-13.
78. Fineberg NA, Pampaloni I, Pallanti S, Ipser J, Stein DJ. Sustained response versus

7. relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder.
International Clinical Psychopharmacology 2007;22(6):313-22.
79. Pallanti S, Sandner C. Treatment of depression with selective serotonin inhibitors:
the role of fluvoxamine. International Journal of Psychiatry in Clinical Practice.
2007; 11(3): 233-238.
80. Pallanti S. Transcultural observations of obsessive-compulsive disorder. American
Journal of Psychiatry. 2008 Feb;165(2):169-70.
81. Pallanti S, Masetti S, Bernardi S, Innocenti A, Markella M, Hollander E. Obsessive
compulsive disorder comorbidity in DBA. Clinical Practice & Epidemiology in Mental
Health. 2008 Mar 10; 4:6.
82. La Malfa G, Lassi S, Bertelli M, Pallanti S, Albertini G. Detecting attention-
deficit/hyperactivity disorder (ADHD) in adults with intellectual disability the use of
Conners' Adult ADHD Rating Scales (CAARS). Research in Developmental
Disabilities. 2008 Mar-Apr;29(2):158-64.
83. Pallanti S. Brain plasticity and brain stimulation in neuropsychiatry: toward
individualized medicine. CNS Spectrums. 2008 Apr;13(4):287-92.
84. Hollander E, Buchsbaum MS, Haznedar MM, Berenguer J, Berlin HA, Chaplin W,
Goodman CR, LiCalzi EM, Newmark R, Pallanti S. FDG-PET study in pathological
gamblers. 1. Lithium increases orbitofrontal, dorsolateral, and cingulated
metabolism. Neuropsychobiology. 2008;58(1):37-47.
85. Pallanti S, Hollander E. Obsessive-compulsive disorder spectrum as a scientific
"metaphor". CNS Spectrums. 2008 Sep;13(9 Suppl 14):6-15.
86. Berlin H.A., Koran L.M., Jenike M.A., Shapira N.A., Chaplin W., Pallanti S.,
Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in
the treatment of obsessive-compulsive disorder. Biological Psychiatry 63 (7), 170S-
170S, 2008-04-01.
87. Pallanti S, Bernardi S. Neurobiology of repeated transcranial magnetic stimulation
in the treatment of anxiety: a critical review. International Clinical
Psychopharmacology 2009 Jul;24(4):163-73.
88. Faravelli C, Lo Sauro C, Castellini G, Ricca V, Pallanti S. Prevalence, and
correlates of mental disorders in a school-survey sample. Clinical Practice &
Epidemiology in Mental Health 2009 Nov 24; 5:1-8.
89. Pallanti S, Castellini G, Chamberlain SR, Quercioli L, Zaccara G, Fineberg NA.
Cognitive event-related potentials differentiate schizophrenia with obsessive-
compulsive disorder (schizo-OCD) from OCD and schizophrenia without OC
symptoms. Psychiatry Research. 2009 Nov 30;170(1):52-60.
90. Potenza MN, Koran LM, Pallanti S. The relationship between impulse-control
disorders and obsessive-compulsive disorder: a current understanding and future
research directions. Psychiatry Research. 2009 Nov 30;170(1):22-31.

8. 91. Bernardi S, Pallanti S. Internet addiction: a descriptive clinical study focusing on
comorbidities and dissociative symptoms. Comprehensive Psychiatry. 2009 Nov-
Dec;50(6):510-6.
92. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation
in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind,
prospective study. CNS Drugs. 2009 Dec;23(12):1047-55.
93. Lisanby SH, Pallanti S, Schlaepfer TE. FDA considers classification of ECT. CNS
Spectrums. 2009 Dec;14(12):668-70.
94. Pallanti S, Bernardi S, Di Rollo A, Antonini S, Quercioli L. Unilateral low frequency
versus sequential bilateral repetitive transcranial magnetic stimulation: is simpler
better for treatment of resistant depression? Neuroscience. 2010;5;167(2):323-8.
95. Pallanti S, Bernardi S, Raglione LM, Marini P, Ammannati F, Sorbi S, Ramat S.
Complex repetitive behavior: punding after bilateral subthalamic nucleus stimulation
in Parkinson's disease. Parkinsonism and Related Disorder. 2010 Jul;16(6):376-80.
96. Cecchelli C, Grassi G, Pallanti S. Aripiprazole Improves Depressive Symptoms, and
Immunological Response to Antiretroviral Therapy in an HIV-Infected Subject with
Resistant Depression. Case Reports in Medicine. 2010; 2010:836214.
97. Schlaepfer TE, Lisanby SH, Pallanti S. Separating hope from hype: some ethical
implications of the development of deep brain stimulation in psychiatric research
and treatment. CNS Spectrums. 2010 May;15(5):285-7.
98. Pallanti S., Schlaepfer T.E., Lisanby S.H. The Clinical Future of Repetitive
Transcranical Magnetic Stimulation and Depression: Separating Hope From Hype.
CNS Spectrums 15 (9), 554-557, 2010.
99. Pallanti S, Haznedar MM, Hollander E, Licalzi EM, Bernardi S, Newmark R,
Buchsbaum MS. Basal Ganglia activity in pathological gambling: a
fluorodeoxyglucose-positron emission tomography study. Neuropsychobiology.
2010;62(2):132-8.
100. Pallanti S. Problematic Internet use: is it more compulsory than rewarding or mood
driven? World Psychiatry. 2010 Jun;9(2):96-7.
101. Bernardi S, Cortese S, Solanto M, Hollander E, Pallanti S. Bipolar disorder and
comorbid attention deficit hyperactivity disorder. A distinct clinical phenotype?
Clinical characteristics and temperamental traits. World Journal of Biological
Psychiatry. 2010 Jun;11(4):656-66.
102. Pallanti S, Bernardi S, Allen A, Chaplin W, Watner D, DeCaria CM, Hollander E.
Noradrenergic function in pathological gambling: blunted growth hormone response
to clonidine. Journal of Psychopharmacology. 2010 Jun;24(6):847-53.
103. Bernardi S, Pallanti S. Successful duloxetine treatment of a binge eating disorder: a
case report. Journal of Psychopharmacology. 2010 Aug;24(8):1269-72.

9. 104. Pallanti S, Borgheresi A, Pampaloni I, Giovannelli F, Bernardi S, Cantisani A,
Zaccara G, Cincotta M. Motor cortex excitability correlates with novelty seeking in
social anxiety: a transcranial magnetic stimulation investigation. Journal of
Neurology. 2010 Aug;257(8):1362-8.
105. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Bruguà M, Carpentier PJ,
Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C,
Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD,
Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak
D, Stes S, Asherson P. European consensus statement on diagnosis and treatment
of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010;3;
10:67.
106. Pallanti S. Augmentation strategies in resistant obsessive-compulsive disorders
(OCD), International Journal of Psychiatry in Clinical Practice 14, 15-16, 2010-11-
01.
107. Pallanti S, Bernardi S, Allen A, Hollander E. Serotonin function in pathological
gambling: blunted growth hormone response to sumatriptan. Journal of
Psychopharmacology. 2010 Dec;24(12):1802-9.
108. Pallanti S. Unique contributions of brain stimulation to the study of consciousness:
where neuroscience meets philosophy. CNS Spectrums. 2010 Mar;15(3):154-6.
109. Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E.
Double-blind, placebo-controlled trial of topiramate augmentation in treatment-
resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry. 2011
May;72(5):716-21. *Participated extensively in conception and trial design,
participated in drafting, reviewing and critical revision of the manuscript
110. Di Rollo A, Pallanti S. Phantom limb pain: low frequency repetitive transcranial
magnetic stimulation in unaffected hemisphere. Case Reports in Medicine. 2011;
2011:130751.
111. Bernardi S, Faraone SV, Cortese S, Kerridge BT, Pallanti S, Wang S, Blanco C. The
lifetime impact of attention deficit hyperactivity disorder: results from the National
Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychological
Medicine. 2011 Aug 16:1-13. *Provided study ideas and concept, participated in the
drafting and revision of the manuscript, and provided mentorship to first author
112. Pallanti S, Grassi G, Sarrecchia ED, Cantisani A, Pellegrini M. Obsessive-
compulsive disorder comorbidity: clinical assessment and therapeutic implications.
Front Psychiatry. 2011; 2:70.
113. Valenti R, Pescini F, Antonini S, Castellini G, Poggesi A, Bianchi S, Inzitari D,
Pallanti S, Pantoni L. Major depression and bipolar disorders in CADASIL: a study
using the DSM-IV semi-structured interview. Acta Neurologica Scandinavica. 2011
Dec;124(6):390-5. *Participated extensively in conception and trial design,
acquisition, analysis and interpretation of data, participated in drafting, reviewing
and critical revision of the manuscript.

10. 114. Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S. An international survey
of reported prescribing practice in the treatment of patients with generalised anxiety
disorder. World Journal of Biological Psychiatry. 2012; 13(7):510-6.
115. Pallanti, S., Grassi, G. and Cantisani, A. (2012). Approaches to Treatment
Resistance. In Obsessive?Compulsive Disorder, J. Zohar (Ed.)
https://doi.org/10.1002/9781119941125.ch5
116. Moretti S, Arunachalam M, Colucci R, Pallanti S, Kline JA, Berti S, Lotti F, Lotti T.
Autoimmune markers in vitiligo patients appear correlated with obsession and
phobia. Journal of the European Academy of Dermatology and Venereology. 2012;
26(7):861-7. *Participated extensively in conception and trial design, participated in
drafting, reviewing and critical revision of the manuscript
117. Pallanti S, Cantisani A, Grassi G, Antonini S, Cecchelli C, Burian J, Cauli G,
Quercioli L. rTMS age-dependent response in treatment resistant depressed
subjects: a mini-review, CNS Spectrums (2012), 17, 24-30.
118. S. Pallanti, A. Di Rollo, S. Antonini, E. Hollander and L.Quercioli Low Frequency
rTMS over Right Dorsolateral Prefrontal Cortex in the Treatment of Resistant
Depression: Cognitive Improvement is Independent from Clinical Response,
Neuropsychobiology 2012 Jun; 65(4):227-35.
119. Moretti S., Arunachalam M., Colucci R., Pallanti S., Kline JA., Berti S., Lotti F., Lotti
T. Autoimmune markers in vitiligo patients appear correlated with obsession and
phobia. Journal of the European Academy of Dermatology and Venereology 2012;
26 (7), 861-867. *Participated extensively in conception, drafting, reviewing and
critical revision of the manuscript.
120. Pallanti S, Salerno L. Pharmacological treatment and management of attention
deficit hyperactivity disorder (ADHD) in adults. Minerva Psichiatrica 2013 Dec;
54(4);297-315. ISSN: 1827-1731
121. Pallanti. S. The Placebo Effect in Clinical Practice. American Journal of Psychiatry
2013 170:8, 931-932
122. Bandinelli F, Prignano F, Bonciani D, Pallanti S, Lotti T, Salaffi F, Bartoli F, Candelieri
A, Giovannini L, Maddali Bongi S, Matucci-Cerinic M. Clinical and demographic
factors influence on anxiety and depression in early psoriatic arthritis (ePsA).
Clinical and Experimental Rheumatology. 2012;31(2):318-9. *Participated
extensively in conception, drafting, reviewing and critical revision of the manuscript
123. Pallanti, S., Grassi, G. and Cantisani, A. (2012). Approaches to Treatment
Resistance. In Obsessive?Compulsive Disorder, J. Zohar (Ed.)
https://doi.org/10.1002/9781119941125.ch5
124. Baldwin DS, Pallanti S, Zwanzger P. Developing a European Research Network to
Address Unmet Needs in Anxiety Disorders. Neuroscience and Biobehavioral
Reviews. 2013; 37(10 Pt 1):2312-7. *Participated extensively in conception and trial
design, participated in drafting, reviewing and critical revision of the manuscript

11. 125. Valenti R, Salvadori E, Pescini F, Poggesi A, Castellini G, Antonini S, Bianchi S,
Inzitari D, Pallanti S, Pantoni L., Facial Affect Recognition in CADASIL Patients.,
Archives of Clinical Neuropsychology 2013;28(1):65-71. *Participated extensively in
conception and trial design, participated in drafting, reviewing and critical revision of
the manuscript
126. Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, McElroy SL, Fong T,
Pallanti S, Hollander E. A double-blind, placebo-controlled trial of topiramate for
pathological gambling. World Journal of Biological Psychiatry. 2013;(2): 121-128.
*Participated extensively in conception and trial design, participated in drafting,
reviewing and critical revision of the manuscript
127. Pallanti S, Cantisani A, Grassi G. Anxiety as a core aspect of schizophrenia.
Current Psychiatry Reports. 2013;15(5):354.
128. Dell'Osso B, Benatti B, Buoli M, Altamura AC, Marazziti D, Hollander E, Fineberg N,
Stein DJ, Pallanti S, Nicolini H, Van Ameringen M, Lochner C, Hranov G,
Karamustafalioglu O, Hranov L, Menchon JM, Zohar J; ICOCS group. The influence
of age at onset and duration of illness on long-term outcome in patients with
obsessive-compulsive disorder, a report from the International College of
Obsessive-Compulsive Spectrum Disorders (ICOCS). European
Neuropsychopharmacology. 2013 Aug; 23(8):865 71. *Participated extensively in
conception and trial design, acquisition and analysis of data, participated in drafting,
reviewing and critical revision of the manuscript
129. Pallanti S, Grassi G, Tofani T, Spitoni S. Pharmacological Treatments for Behavioral
Addictions: From Behavioral Dimensions to the Research Domain Criteria Based
Target. Current Psychopharmacology, 2013; 2(3):183-189.
130. Marras A, Pallanti S. Transcranial magnetic stimulation for the treatment of
pharmacoresistant nondelusional auditory verbal hallucinations in dementia. Case
Reports in Psychiatry. 2013; 2013:930304.
131. Pallanti S, Hollander E. Pharmacological, experimental therapeutic, and transcranial
magnetic stimulation treatments for compulsivity and impulsivity. CNS Spectrums.
2014; 19(1):50-61.
132. Carelli R, Pallanti S. Streptococcal infections of skin and PANDAS. Dermatologic
Therapy. 2014 Jan; 27(1):28-30.
133. Grassi G, Poli L, Cantisani A, Righi L, Ferrari G, Pallanti S. Hypocondriasis and
obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs
other atypical antipsychotics. CNS Spectrums. 2014; 9(4):340-6.
134. Van Ameringen S, Simpson W, Patterson B, Dell'Osso B, Finebg n, Hollander E,
Hranov L, Hranov G, Lochner C, Karamustafalioglu O, Marazziti D, Menchon JM,
Nicolini H, Pallanti S, Stein DJ, Zohar, J. Pharmachological treatment strategies in
obsessive-compulsive disorder: A cross-sectional view in nine international OCD
centers. Journal of Psychopharmacology 2014; 28(6):596-602. *Participated
extensively in conception and trial design, authorship of sections of the manuscript,

12. participated in drafting, reviewing and critical revision of the manuscript
135. Di Rubbo R., Sogaro E., Pallanti, S. Communicative evolutive psychotherapy
adapted for the psychodynamic group setting in the treatment of pathological
interpersonal dynamics of identity. Dynamische Psychiatrie. 2013; 46(3): 204-233.
136. Pallanti S, Grassi G, Cantisani A. Emerging drugs to treat obsessive-compulsive
disorders. Expert opin Emerg Drugs, 2014 Mar; 19(1):66-77.
137. Pallanti S, Grassi G, Antonini S, Quercioli L, Salvadori E, Hollander E. rTMS in
resistant mixed states: An exploratory study. J Affect Disord. 2014; 157:66-71.
138. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondasetron augmentation
in patients with obsessive-compulsive disorder who are inadequate responders to
serotonin reuptake inhibitors: improvement with treatment and worsening following
discontinuation. Eur Neuropsychopharmacol. 2014; 24(3):375-380.
139. Pallanti S, Grassi G, Ramella Cravaro V, Goodman W.K. From Psychopathology to
neurocircuits: what we can learn from DBS? The case of obsessive-compulsive
disorder. J. Psychopathol. 2014; 20:27-32.
140. Aguglia E, Biggio G, Signorelli MS, Mencacci C; Steering Committee on behalf of
the STIMA-D Investigators. Italian Study on Depressive Disorders (STudio Italiano
MAlattia Depressiva, or STIMA-D): a nationwide snapshot of the status of treatment
for major depression. Pharmacopsychiatry.2014 May;47(3), 105-10. *Member:
Pallanti S. *Acquisition of data
141. Pallanti S, Tofani T, Zanardelli M, Di Cesare mannelli L, Ghelardini C. BDNF and
ARTEMIN are increased in drug-naive non-depressed GAD patients: preliminary
data. International Journal of Psychiatry in Clinical Practice. 2014; 18(4):255-60.
142. Lochner C, Fineberg NA, Zohar J, Van Ameringen M, Juven_Wetzler A, Altamura
AC Cuzen NL, Hollander E, Denys D, Nicolini H, Dell'Osso B, Pallanti S, Stein DJ,
Comorbidity in obsessive-compulsive disorder (OCD): a report from the
International College of Obsessive-Compulsive Spectrum Disorder (ICOCS).
Comprehensive Psychiatry. 2014;55(7):1513-9. *Participated extensively in
conception and trial design, drafting, reviewing and critical revision of the
manuscript
143. Pallanti S, Grassi G. Pharmacologic treatment of obsessive-compulsive disorder
comorbidity. Expert Opin Pharmacother. 2014;15(17):2543-52.
144. Mucci A, Rucci P, Rocca P, Bucci P, Gibertoni D, Merlotti E, Galderisi S, Maj M;
Italian Network for Research on Psychoses. The Specific Level of Functioning
Scale: construct validity, internal consistency and factor structure in a large Italian
sample of people with schizophrenia living in the community. Schizophrenia
Research. 2014; 159(1):144-50. *Member: Pallanti S. *Acquisition of data
145. Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D,
Aguglia E, Amore M, Bellomo A, Biondi M, Brugnoli R, Dell'Osso L, De Ronchi D, Di
Emidio G, Di Giannantonio M, Fagiolini a, Marchesi C, Monteleone P, Oldani L,

13. Pinna F, Roncone R, Sacchetti E, Santonastaso P, Siracusano A, Vita A, Zeppegno
P, Maj M; Italian Network for Research on Psychoses. The influence of illness-
related variables, personal resources and context-related factors on real-life
functioning of people with schizophrenia. World Psychiatry. 2014; 13(3):275-87.
*Member: Pallanti S. *Acquisition of data
146. Cantisani, A., Grassi, G., Pagano, L., Comanducci, A., Lanzo, G., Amantini, a.,
Grippo, a., Salerno, L., Pallanti, S. Neurophysiological alterations in adults with
attention deficit/hyperactivity disorder: an event-related potential study. European
Neuropsychopharmacology 24:S714-S715 · October 2014. DOI: 10.1016/S0924-
977X(14)71151-4
147. Grassi G, Godini L, Grippo A, Piccagliani D, Pallanti S. Enhancing Cognitive-
behavioral Therapy with Repetitive Transcranial Magnetic Stimulation in Refractory
Obsessive-Compulsive-Disorder: a Case Report. Brain Stimulation. 2015; 8(1):160-
1.
148. Pallanti S, Salerno L. Raising attention to attention deficit hyperactivity disorder in
schizophrenia. World Journal of Psychiatry. 2015;5(1):47-55.
149. Grassi, G., Pallanti, S. Citalopram Pulse-Loading for Treatment-Resistant
Obsessive-Compulsive Disorder: Preliminary Data from an Open-Label Trial.
European Neuropsychopharmacology, Volume 26, Issue 5, 2016, Pages 898-899,
ISSN 0924-977X, https://doi.org/10.1016/j.euroneuro.2015.06.034.
150. Dell'Osso B, Nicolini H, Lanzagorta N, Benatti B, Spagnolin G, Palazzo MC,
Marazziti D, Hollander E, Fineberg N, Stein DJ, Pallanti S, Van Ameringen M,
Lochner C, Hranov N, Karamustafalioglu O, Hranov L, Zohar J, Denys d, Altamura
AC, Menchon JM. Cigarette smoking in patients with obsessive compulsive
disorder: a report from International College of Obsessive Compulsive Spectrum
Disorder (ICOCS). CNS Spectrums. 2015; 20(5):469-73. *Participated extensively
in conception, participated in drafting, reviewing and critical revision of the
manuscript
151. Uzunova G, Pallanti S, Hollander E. Excitatory/inhibitory imbalance in autism
spectrum disorder: Implications for interventions and therapeutics. World Journal of
Biological Psychiatry. 2015; 15:1-13. *Authorship of sections of the manuscript,
participated in drafting, reviewing and critical revision of the manuscript
152. Pallanti, S., Grassi G, Marras A, Hollander E. Can we modulate obsessive-
compulsive networks with neuromodulation? J Psychopatol, 21:262-265.
153. Pallanti, S., Marras A, Grassi G. Outcomes with neuromodulation in obsessive-
compulsive disorder. Psych Annals, 45(6):316-320.
154. Pallanti, S., Marras, A. Transcranial Magnetic Stimulation Treatment for Motor
Symptoms in Parkinson's Disease: A Review of Two Decades of Studies. Journal of
Alzheimer's Disease & Parkinsonism. 05. 10.4172/2161-0460.1000191.
155. Pallanti, S., Marras, A. Transcranial Magnetic Stimulation in Alzheimer's Disease: A
Review of Investigational and Therapeutic Findings. J Alzheimers Dis Parkinsonism

14. 5:187. doi:10.4172/2161-0460.1000187
156. Grassi, G., Molesti E., Lori S., Pallanti S., Cheli E., Marras A. "OR-38:
neuromodulation of decision-making networks with alfaEEG-guided repetitive
transcranic magnetic stimulation: preliminary results from a pilot study." Journal of
Behavioral Addictions, vol. 5, no. S1, 2016, p. 17+.
157. Grant J E, Fineberg N, Van Ameringen A, Cath D, Visser H, Carmi L, Pallanti S,
Hollander E, Van Balkom A J, New treatment models for compulsive disorders.
European Neuropsychopharmacology 2016; 26(5):877-84. *Participated extensively
in conception, acquisition of data, authorship of sections of the manuscript
158. Grassi G, Pallanti S, Righi L, Figee M, Mantione M, Denys D, Piccagliani D, Rossi
A, Stratta P. Think twice: Impulsivity and decision making in obsessive-compulsive
disorder. Journal of Behavioral Addiction 2015;4(4):263-72. *Provided study ideas,
participated in the drafting, reviewing and revision of the manuscript, and provided
mentorship to first author
159. Pallanti S, Marras A, Salerno L, Makris N, Hollander E. Better than treated as usual:
Transcranial magnetic stimulation augmentation in selective serotonin reuptake
inhibitor-refractory obsessive-compulsive disorder, mini-review, and pilot open-label
trial. Journal of Psychopharmacology. 2016; 30(6):568-78.
160. Menchon JM, Van Ameringen M, Dell'Osso B, Denys D, Figee M, Grant JE,
holander E, Marazziti D, Nicolini H, Pallanti S, Ruck R, stein DJ, Andersson E,
bipeta R, Cath DC, drummond L, Feusner J, Geller DA, Hranov , lochner C,
Matsunaga H, McCabe RE, Mpavaenda D, Nakamae T, O'Kearney R, pasquini M,
Perez Rivera R, Poyurovsky M, Real E, do Rosario MC, Sreni N, Swinson RP,
Vulink N, Zphar J, Fineberg N. Standards of care for obsessive-compulsive
disorders centres. International Journal of Psychiatry in Clinical Practice.
2016;20(3):204-8. *Participated extensively in conception and trial design,
acquisition of data and in drafting
161. Marras A, Fineberg N, Pallanti S. Obsessive compulsive and related disorders:
comparing DSM-5 and ICD-11. CNS Spectrums. 2016;21(4):324-33.
162. Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, bourin M, Chamberlain SR,
Cinosi E, Davies S, Domscchke K, Fineberg N, Grunblatt E, Jarema M, Kim YK,
Maron E, Masdrakis V, Mikova O, Nutt D, Pallanti S, Pini S, Strohle A, Thibaut F,
Vaghi MM, Won E, Wedekind D, Wichniak A, Woolley J, Zwanzger P, Riederer P.
Biological markers for anxiety disordrs, OCD and PTSD: a consensus statement.
Part II: Neurochemistry, neurophisiology and neurocognition. World Journal of
Biological Psychiatry. 2016; 15:1-53. *Participated extensively in conception and
trial design, acquisition,authorship of sections of the manuscript
163. Grassi G, Micheli L, Di Cesare Mannelli L, Compagno E, Righi L, Ghelardini C,
Pallanti S. Atomoxetine for hoarding disorder: A pre-clinical and clinical
investigation. J Psychiatr Res. 2016 Dec;83:240-248. doi:
10.1016/j.jpsychires.2016.09.012. Epub 2016 Sep 14. PMID: 27665536.
164. Dell'Osso B, Benatti B, Hollander E, Fineberg N, Stein DJ, Lochner C, Nicolini H,

15. Lanzagorta N, Palazzo C, altamura AC, Marazziti D, Pallanti S, Van Ameringen M,
Karamustafalioglu O, Drummond LM, Hrano L, Figee M, Grant JE, Zohar J, Denys
D, Menchon JM. Childhood, adolescent and adult age at onset and related clinical
correlates in obsessive-compulsive disorder: a report from the International College
of Obsessive-Compulsive Spectrum Disorders (ICOCS). International Journal of
Psychiatry in Clinical Practice. 2016; 19:1-8. *Participated extensively in conception
and trial design, acquisition of data and in drafting
165. Pallanti S. ICD and DSM: Neuroplasticity and Staging are still missing. CNS
Spectrums. 2016 Aug:21(4):276-8.
166. Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D,
Aguglia E, Amore M, Blasi G, Comparelli A, Di Giannantonio M, Goracci A,
Marchesi C, Monteleone P, Montemagni C, Pinna F, Roncone R, Siracusano A,
Stratta P, Torti MC, Vita A, Zeppegno P, Chieffi M, Maj M; Italian Network for
Research on Psychoses. Pathways to functional outcome in subjects with
schizophrenia living in the community and their unaffected first-degree relatives.
Schizophr Res 2016; 175(1-3):154-60. *Member: Pallanti S. *Participated
extensively in conception and trial design, acquisition, analysis of data, reviewing
and critical revision of the manuscript
167. Rocca P, Galderisi S, Rossi A, Bertolino A, Rucci P, Gibertoni D, Montemagni C,
Sigaudo M, Mucci A, Bucci P, Acciavatti T, Aguglia E, Amore M, Bellomo A, De
Ronchi D, Dell'Osso L, Di Fabio F, Girardi P, Goracci A, Marchesi C, Monteleone P,
Niolu C, Pinna F, Roncone R, Sacchetti E, Santonastaso P, Zeppegno P, Maj M;
Italian Network for Research on Psychoses. Social cognition in people with
schizophrenia: a cluster-analytic approach. Psychol Med 2016 Oct;46(13):2717-
2729 *Member: Pallanti S. *Participated extensively in conception and trial design,
acquisition, participated in drafting, reviewing and critical revision of the manuscript
168. Menchón JM, van Ameringen M, Dell'Osso B, Denys D, Figee M, Grant JE,
Hollander E, Marazziti D, Nicolini H, Pallanti S, Ruck C, Shavitt R, Stein DJ,
Andersson E, Bipeta R, Cath DC, Drummond L, Feusner J, Geller DA, Hranov G,
Lochner C, Matsunaga H, McCabe RE, Mpavaenda D, Nakamae T, O'Kearney R,
Pasquini M, Pérez Rivera R, Poyurovsky M, Real E, do Rosário MC, Soreni N,
Swinson RP, Vulink N, Zohar J, Fineberg N. Standards of care for obsessive-
compulsive disorder centres. Int J Psychiatry Clin Pract. 2016 Sep;20(3):204-8.
*Participated extensively in conception and trial design, acquisition of data and in
drafting, reviewing and critical revision of the manuscript
169. Giordano F, Cavallo M, Spacca B, Pallanti S, Tomaiuolo F, Pieraccini F, Fagiolini A,
Grandoni M, Melani F, Zicca A, Sestini S, Genitori L. Deep Brain Stimulation of the
Anterior Limb of the Internal Capsule May Be Efficacious for Explosive Aggressive
Behaviour. Stereotact Funct Neurosurg. 2016 Nov 1;94(6):371-378. *Participated
extensively in conception and trial design, acquisition of data and in drafting
170. Dell'Osso B, Benatti B, Hollander E, Fineberg N, Stein DJ, Lochner C, Nicolini H,
Lanzagorta N, Palazzo C, Altamura AC, Marazziti D, Pallanti S, Van Ameringen M,
Karamustafalioglu O, Drummond LM, Hranov L, Figee M, Grant JE, Zohar J, Denys
D, Menchon JM. Childhood, adolescent and adult age at onset and related clinical
correlates in obsessive-compulsive disorder: a report from the International College

16. of Obsessive-Compulsive Spectrum Disorders (ICOCS). Int J Psychiatry Clin Pract.
2016 Nov;20(4):210-7. *Participated extensively in conception and trial design,
acquisition of data and in drafting, reviewing and critical revision of the manuscript
171. Grassi G, Micheli L, Di Cesare Mannelli L, Compagno E, Righi L, Ghelardini C,
Pallanti S. Atomoxetine for hoarding disorder: A pre-clinical and clinical
investigation. J Psychiatr Res. 2016 Dec; 83:240-248.
172. Chiariello F, Spitoni S, Hollander E, Pallanti S. An expert opinion on
PANDAS/PANS: highlights and controversies. International Journal of Psychiatry in
Clinical Practice 2017; 1-8 Published online: 13 Feb 2017
173. Salerno L, Makris N, Pallanti S. Raadult ADHD: a key feature. Journal of
Psychopathology 2016; 22:135-140.
174. Pallanti S. Biological Markers for Anxiety Disorders, OCD and PTSD - A Consensus
Statement - Part II: Neurochemistry, Neurophysiology and Neurocognition. The
World Journal of Biological Psychiatry World J Biol Psychiatry. 2017 Apr;18(3):162-
214.
175. Dell'Osso B, Benatti B, Arici C, Palazzo C, Altamura AC, Hollander E, Fineberg N,
Stein DJ, Nicolini H, Lanzagorta N, Marazziti D, Pallanti S, van Ameringen M,
Lochner C, Karamustafalioglu O, Hranov L, Figee M, Drummond L, Rodriguez CI,
Grant J, Denys D, Menchon JM, Zohar J. Prevalence of suicide attempt and clinical
characteristics of suicide attempters with obsessive-compulsive disorder: a report
from the International College of Obsessive-Compulsive Spectrum Disorders
(ICOCS). CNS Spectr. 2017 Mar 16:1-8.
176. Dell'Osso B, Marazziti D, Albert U, Pallanti S, Gambini G, Tundo A, Zanaboni C,
Servello D, Rizzo R, Scalone L, Benatti B, Altamura C, Porta M. Parsing the
phenotype of obsessive-compulsive tic disorder (OCTD): a multidisciplinary
consensus. Int J Psychiatry Clin Pract. 2017 Jun;21(2):156-159.
177. Salerno L, Burian I, Pallanti S. A new generation rating scale for depression:
Reliability and Validity of the Italian version of Symptoms of Depression
Questionnaire (SDQ), an RDoC-oriented depression comprehensive assessment.
Journal of Psychopathology, 2017 23:1-12.
178. Grassi, G., Pacini, S., Cecchelli C., Pallanti, S. Enhancing inhibition processes
during cognitive-behavioral therapy in obsessive-compulsive disorder with repetitive
transcranial magnetic stimulation. S1009. European Neuropsychopharmacology,
2017
179. Grassi, G., & Pallanti, S. (2017). Common Neural Networks Between OCD and
Behavioural Addictions: Is LCD a Behavioural Addiction? European Psychiatry,
41(S1), S21-S22. Doi:10.1016/j.eurpsy.2017.01.120
180. Lusicic A, Schruers KR, Pallanti S, Castle DJ. Transcranial magnetic stimulation in
the treatment of obsessive-compulsive disorder: current perspectives.
Neuropsychiatr Dis Treat. 2018 Jun 29;14:1721-1736. doi: 10.2147/NDT.S121140.
PMID: 29988759; PMCID: PMC6029675.

17. 181. Micheli L., Spitoni S, Di Cesare Mannelli L., Billa A.R., Pallanti S. Bacopa Monnieri
as augmentation therapy in the treatment of anhedonia,preclinical and clinical
evaluation. 01 April 2020 http10.1002/ptr.6684
182. Grassi G, Figee M, Ooms P, Righi L, Nakamae T, Pallanti S, Schuurman R, Denys
D. Impulsivity and decision-making in obsessive-compulsive disorder after effective
deep brain stimulation or treatment as usual. CNS Spectr. 2018 Jun 4:1-7
183. Burchi E, Pallanti S. Antibiotics for PANDAS? Limited Evidence: Review and
Putative Mechanisms of Action. Prim Care Companion CNS Disord. 2018 May
3;20(3).
184. Burchi E, Pallanti S. Diagnostic Issues in Early-Onset Obsessive-Compulsive
Disorder and Their Treatment Implications.Curr Neuropharmacol. 2018 Apr 26.
185. Fineberg NA, Chamberlain SR, Menchon J, Demetrovics D, Grünblatt E, Pallanti S,
Carmi L, Billieux J, King D, Dellosso B, Van Ameringen M, Hall N, Potenza M,
Hollander E, Zohar J and the COST Action EU-PUI Network. Manifesto for a
European Research Network into Problematic Usage of the Internet. 2018, in
submission.
186. Fineberg NA, Demetrovics Z, Stein DJ, Ioannidis K, Potenza MN, Grünblatt E,
Brand M, Billieux J, Carmi L, King DL, Grant JE, Yücel M, Dell'Osso B, Rumpf HJ,
Hall N, Hollander E, Goudriaan A, Menchon J, Zohar J, Burkauskas J, Martinotti G,
Van Ameringen M, Corazza O, Pallanti S; COST Action Network, Chamberlain SR.
Version 2. Manifesto for a European research network into Problematic Usage of
the Internet. Eur Neuropsychopharmacol. 2018 Nov;28(11):1232-1246. Doi:
10.1016/j.euroneuro.2018.08.004. Epub 2018 Oct 10. PMID: 30509450
187. Burchi E, Hollander E, Pallanti S. From Treatment Response to Recovery: A
Realistic Goal in OCD. Int J Neuropsychopharmacol. 2018 Nov 1;21 (11):1007-
1013. doi: 10.1093/ijnp/pyy079. PMID:30184141
188. Grassi G, Pallanti S. Expert Opinion Pharmacother. 2018 Oct;19(14):1541-1550.
Doi:10.1080/14656566.2018.1528230. Epub 2018 Oct 15. PMID:3021070
189. Sali L, Ventura L, Grazzini G, Borgheresi A, Delsanto S, Falchini M, Mallardi B,
Mantellini P, Milani S, Pallanti S, Zappa M, Mascalchi M. Patients' experience of
screening CT colonography with reduced and full bowel preparation in a
randomised trial. Eur Radiol. 2018 Nov 6. doi: 10.1007/s00330-018-5808-1. [Epub
ahead of print] PMID:30402705
190. Scarpino, M, Lanzo G, Salimova M, Lolli F, Del Vecchio A, Cossu Cesarina,
Bastianelli M, Occupati B, Lanzi C, Pallanti S, Amantini A, Mannaioni G, Grippo A.
Efficacy of high-frequency (15Hz) repetitive transcranial magnetic stimulation
(rTMS) of the left premotor cortex/dorsolateral prefrontal cortex in decreasing
cocaine intake (the Magne Tox study): A study protocol for a randomized placebo-
controlled pilot trial. Neurophysiologie Clinique, 10 2018
191. Grassi, G., Pallanti, S. Current and up-and-coming pharmacotherapy for obsessive-

18. compulsive disorder in adults, Expert Opinion on Pharmacotherapy, 19:14, 1541-
1550, DOI: 10.1080/14656566.2018.1528230 2018
192. J.J.S. Kooija, D. Bijlengaa, L. Salerno, R. Jaeschkea, I. Bittera, J. Balázsa, J.
Thomea, G. Doma, S. Kaspera, C. Nunes Filipea, S. Stesa, P. Mohra, S.
Leppämäkia, M. Casas Bruguéa, J. Bobesa, J.M. Mccarthya, V. Richartea, A. Kjems
Philipsena, A. Pehlivanidis,b , A. Niemela, B. Styr, B. Semerci, B. Bolea-Alamanac,
D. Edvinsson, D. Baeyens, D. Wynchank, E. Sobanski, A. Philipsen, F. McNicholas,
H. Caci, I. Mihailescu, I. Manor,b , I. Dobrescu,b , J. Krause,b , J. Fayyad, J.A.
Ramos-Quiroga, K. Foeken, F. Rad, M. Adamou, M. Ohlmeier, M. Fitzgerald, M.
Gill, M. Lensing, N. Motavalli Mukaddes, P. Brudkiewicza, P. Gustafsson, P. Tani, P.
Oswald, P.J. Carpentier, P. De Rossi, R. Delorme, S. Markovsk, Simosk, S. Pallanti,
S. Young, S. Bejerot, T. Lehtonen, J. Kustow, U. Müller-Sedgwick, T. Hirvikoski, V.
Pironti, Y. Ginsberg, Z. Félegeházy, M.P. Garcia-Portilla, P. Asherson., Updated
European Consensus Statement on diagnosis and treatment of adult ADHD;
European Psychiatry 56 (2019) 14-34 accepted 3 Nov 2018
193. Fineberg NA, Demetrovics Z, Stein DJ, Ioannidis K, Potenza MN, Grünblatt E,
Brand M, Billieux J, Carmi L, King DL, Grant JE, Yücel M, Dell'Osso B, Rumpf HJ,
Hall N, Hollander E, Goudriaan A, Menchon J, Zohar J, Burkauskas J, Martinotti G,
Van Ameringen M, Corazza O, Pallanti S; COST Action Network, Chamberlain SR.,
Manifesto for a European research network into Problematic Usage of the Internet.
Eur Neuropsychopharmacol. 2018 Nov;28(11):1232-1246. doi:
10.1016/j.euroneuro.2018.08.004. Epub 2018 Oct 10. PMID:30509450
194. Scarpino M, Lanzo G, Salimova M, Lolli F, Del Vecchio A, Cossu C, Bastianelli M,
Occupati B, Lanzi C, Pallanti S, Amantini A, Mannaioni G, Grippo A., Efficacy of
high-frequency (15Hz) repetitive transcranial magnetic stimulation (rTMS) of the left
premotor cortex/dorsolateral prefrontal cortex in decreasing cocaine intake (the
MagneTox Study): A study protocol for a randomized placebo-controlled pilot trial.
Neurophysiol Clin. 2019 Feb;49(1):1-9. doi: 10.1016/j.neucli.2018.10.002. Epub
2018 Oct 26. PMID:30712533
195. Grassi, G., Pacini, S., Cecchelli, C., Pallanti, S. Enhancing Cognitive-Behavioral
Therapy for Obsessive-Compulsive Disorder with Transcranic Magnetic Stimulation:
A proof of concept. European Neuropsychopharmacology, Volume 28, Issue 6,
2018, Pages 766-767, ISSN 0924-977X,
https://doi.org/10.1016/j.euroneuro.2017.10.008.
196. Grassi G., Makris N., Pallanti S. Olfaction in gambling disorder: an exploratory
study. Journal of Behavioral Addictions. ICBA2018 / April 23-25, 2018 / Cologne,
Germany. Vol 7., Supplement 1. www.academiai.com
197. Fineberg NA, Dell'Osso B, Albert U, Maina G, Geller D, Carmi L, Sireau N, Walitza
S, Grassi G, Pallanti S, Hollander E, Brakoulias V, Menchon JM, Marazziti D,
Ioannidis K, Apergis-Schoute A, Stein DJ, Cath DC, Veltman DJ, Van Ameringen M,
Fontenelle LF, Shavitt RG, Costa D, Diniz JB, Zohar J., Early intervention for
obsessive compulsive disorder: An expert consensus statement. Eur
Neuropsychopharmacol. 2019 Feb 14. pii: S0924-977X(19)30159-2. doi:
10.1016/j.euroneuro.2019.02.002. [Epub ahead of print] PMID:30773387

19. 198. HollanderE., Van Ameringen M., Nicolini H., Zohar J., Pallanti S., Nezgoverova V.,
Fineberg N. E. 01.01 Pharmacological Treatment of resistant OCD. European
Neuropsychopharmacology, 2019 vol29, S32, Elsevie
199. Marras A., Gavazzi G., Grassi G., Rathi Y., Mascalchi M., Makris N., Camprodon
J.A., Pallanti S. Abstract59: Modulating Inhibitory Control Networks in Gambling
Disorder with Theta Burst Stimulation. Brain Stimulation: Basic, Translational, and
Clinical Research in Neuromodulation. Elsevier. 2019 Mar 1., Vol 12, issue 2, e21.
200. Salerno L., Ramat S., Solari G, Grassi G., Pallanti S. Parkinson's Disease with
Impulse Control Disorders: Higher Prevalence (Frequency) of Symptoms of
Attention Deficit Hyperactivity Disorder International Journal of Clinical Psychiatry
2019, 7(1): 1-7 DOI: 10.5923/j.ijcp.20190701.01
201. Burchi E., Makris N., Lee MR., Pallanti S., Hollander E. Compulsivity in Alcohol Use
Disorder and Obsessive Compulsive Disorder: Implications for Neuromodulation.
2019, Front. Behav. Neurosci. | doi: 10.3389/fnbeh.2019.00070
202. Sacchetti, E. Pallanti, S. Bowden-Jones, H. (2019). Archives of Behavioral
Addictions: A new journal for a new era.Archives of Behavioral Addictions, 1(1).
doi:10.30435/ABA.01.2019.01
203. Grassi G., Makris N., Pallanti S. Addicted to compulsion: assessing three core
dimensions of addiction across obsessive-compulsive disorder and gambling
disorder. CNS Spectr. 2019 May 20:1-10. doi: 10.1017/S1092852919000993. [Epub
ahead of print] PMID:31106718
204. Dell'Osso B., Vismara M., Benatti B., Cirnigliaro G., Grancini B., Fineberg N., Van
Ameringen M., Hollander E., Stein D., Menchon JM., Rodriguez C., Nicolini H.,
Lanzagorta N., Pallanti S., Grassi G., Lochner C., Marazziti D., Hranov G.,
Karamustafalioglu O., Hranov L., Zohar J. Lifetime bipolar disorder comorbidity and
related clinical characteristics in patients with primary obsessive compulsive
disorder: a report from the International College of Obsessive-Compulsive
Spectrum Disorders (ICOCS). CNS Spectrums. doi 10.1017/S1092852919001068
Published online: 27 May 2019
205. Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti
A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone,
brexpprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019
Jun 26. pii: S0924-977X (19)30266-4. doi: 10.1016/j.euroneuro.2019.06.008. [Epub
ahead of print] Review. PMID:31255396
206. Davis JM. Commentary on: Corponi F., Fabbri C, Bitter, I. Montgomery, S., Vieta, E.,
Kaspar, S., Pallanti S., Serretti A. Novel antipsychotics specificity profile: A clinically
oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur
Neuropsychopharmacol. 2019 Sep;29(9):1061-1062. doi:
10.1016/j.euroneuro.2019.07.001. Epub 2019 Jul 29. No abstract available.
PMID:31371104
207. Kooij JJS, Bijenga D, Salerno L, Jaeschke R, Bitter I, Balazs J, Thome J, Dom G,
Kasper S, Nunes FC, Stes S, Mohr P, Leppamaki S, Casas M, Bobes J, Mccarthy

20. JM, Richarte V, Kjems PA, Pehlivanidis A, Niemela A, Styr B, Semerci B, Bolea-
Alamanac B, Edvinsson D, Baeyens D, Wynchank D, Sobanski E, Philipsen A,
McNicholas F, Caci H, Mihailescu I, Manor I, Dobrescu I, Saito T, Krause J, Fayyad
J, Ramos-Quiroga JA, Foeken K, Rad F, Adamou M, Ohlmeier M, Fitzgerald M, Gill
M, Lensing M, Motavalli Mukaddes N, Brudkeiwicz P, Gustafsson P, Tani P, Oswald
P, Carpentier PJ, De Rossi P, Delorme R, Markovska Simoska S, Pallanti S, Young
S, Bejerot S, Lehtonen T, Kustow J, Muller-Sedgwick U, Hirvikoski T, Pironti V,
Ginsberg Y, Felegyhazy Z, Garcia-Portilla MP, Asherson P. Updated European
Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry
2019 Feb; 56:14-34. doi: 10.1016/j.eurpsy.2018.11.001. Epub 2018 Nov 16.
208. Pallanti, S. (2018). Meet our New Field Editor. CNS Spectrums, 23(6), 423-423.
doi:10.1017/S1092852918001530
209. Pasquini M., Brakoulias V., Pallanti S. Editorial: Advances in Biological Approaches
to Treating Resistant/Refractory Obsessive-Compulsive and Related Disorders.
Front Psychiatry. 2020 Feb 25; 11:93. doi: 10.3389/fpsyt.2020.00093. ECollection
2020.
210. Fineberg N.A., Van Ameringen M., Drummond L, Hollander E., Stein D.J. Geller D.,
Walitza S., Pallanti S., Pellegrini L., Zohar J., Rodriguez C.I., Menchon J.M.,
Morgado P., Mpavaenda D., Fontenelle L.F., Feusner J.D., Grassi G., Lochner C.,
Veltman D.J., Sireau N., Carmi L., Adam D., Nicolini H., Dell'Osso B. cu obsessive-
compulsive disorder (OCD) under COVID-19: A clinician's guide from the
International College of Obsessive. Compulsive Spectrum Disorders (ICOCS) and
the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of
the European College of Neuropsychopharmacology.
Doi.org/10.1016/j.comppsych.2020.152174. 0010-440X/© 2020 The Author(s).
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
211. Fontenelle LF, Oldenhof E, Eduarda Moreira-de-Oliveira M, Abramowitz JS, Antony
MM, Cath D, Carter A, Dougherty D, Ferrão YA, Figee M, Harrison BJ, Hoexter M,
Soo Kwon J, Küelz A, Lazaro L, Lochner C, Marazziti D, Mataix-Cols D, McKay D,
Miguel EC, Morein-Zamir S, Moritz S, Nestadt G, O'Connor K, Pallanti S, Purdon C,
Rauch S, Richter P, Rotge JY, Shavitt RG, Soriano-Mas C, Starcevic V, Stein DJ,
Steketee G, Storch EA, Taylor S, van den Heuvel OA, Veale D, Woods DW,
Verdejo-Garcia A, Yücel M. A Transdiagnostic perspective of constructs underlying
obsessive-compulsive and related idsorders: An international Delphi consensus
study. Aust N Z J Psychiatry. 2020 May 4:4867420912327. doi:
10.1177/0004867420912327. [Epub ahead of print] PMID: 32364439
212. Benatti B, Ferrari S, Grancini B, Girone N, Briguglio M, Marazziti D, Mucci F,
Dell'Osso L, Gambini O, Demartini B, Tundo A, Necci R, De Berardis D, Galentino
R, De Michele S, Albert U, Rigardetto S, Maina G, Grassi G, Pallanti S, Amerio A,
Amore M, Priori A, Servello D, Viganò C, Bosi M, Colombo A, Porta M, Dell'Osso B.
Suicidal ideation and suicidal attempts in patients with obsessive-compulsive tic-
related disorder vs obsessive-compulsive disorder: results of a multicenter Italian
study. CNS Spectr. 2020 May 6:1-8. doi: 10.1017/S1092852920001157. [Epub
ahead of print] PMID: 32372727

21. 213. Galderisi S, Rucci P, Mucci A, Rossi A, Rocca P, Bertolino A, Aguglia E, Amore M,
Bellomo A, Bozzatello P, Bucci P, Carpiniello B, Collantoni E, Cuomo A, Dell'Osso L,
Di Fabio F, di Giannantonio M, Gibertoni D, Giordano GM, Marchesi C, Monteleone
P, Oldani L, Pompili M, Roncone R, Rossi R, Siracusano A, Vita A, Zeppegno P, Maj
M; Italian Network for Research on Psychoses*.The interplay among
psychopathology, personal resources, context-related factors and real-life
functioning in schizophrenia: stability in relationships after 4 years and differences
in network structure between recovered and non-recovered patients. *Member:
Pallanti, S. World Psychiatry. 2020 Feb;19(1):81-91. doi: 10.1002/wps.20700.PMID:
31922687
214. Fontenelle, L. F., Oldenhof, E., Eduarda Moreira-de-Oliveira, M., Abramowitz, J. S.,
Antony, M. M., Cath, D. C., Carter, A., Dougherty, D., Ferrão, Y. A., Figee, M.,
Harrison, B. J., Hoexter, M., Soo Kwon, J., Küelz, A., Lazaro, L., Lochner, C.,
Marazziti, D., Mataix-Cols, D., McKay, D., Miguel, E.C., Morein-Zamir, S., Moritz, S.,
Nestadt, G., O'Connor, K., Pallanti, S., Purdon, C., Rauch, S., Richte, P., Rotge,
J.Y., Shavitt, R.G., Soriano-Mas, C., Stein, D.J., Steketee, G., Sorch, E.A., Taylor,
S., Van den Heuvel, O.A., Veale, D., Woods, D.W., Verdejo-Garcia, A., Yucel, M.
The International OCRDs Neuroscience Consensus Group (2020). A
transdiagnostic perspective of constructs underlying obsessive-compulsive and
related disorders: An international Delphi consensus study. Australian & New
Zealand Journal of Psychiatry, 54(7), 719-731.
https://doi.org/10.1177/0004867420912327
215. Sali, L., Ventura, L., Grazzini, G., Borgherese, A., Delsanto, S., Falchini, M.,
Mallardi, B., Mantellini, P., Milani, S., Pallanti, S., Zappa M., Mascalchi M. Patients'
experience of screening CT colonography with reduced and full bowel preparation
in a randomised trial. Eur Radiol 29, 2457-2464 (2019).
https://doi.org/10.1007/s00330-018-5808-1
216. Fineberg, Naomi A., Hollander, Eric., Pallanti, Stefano., Walitza, Susanne Grünblatt,
Ednag,,h,,i; Dell'Osso, Bernardo Mariaj,,k,,l,,m; Albert, Umberton; Geller, Daniel A.o;
Brakoulias, Vlasiosp,,q; Janardhan Reddy, Y.C.r; Arumugham, Shyam Sundarr;
Shavitt, Roseli G.s; Drummond, Lynnet; Grancini, Benedettab,,j; De Carlo, Verab,,j;
Cinosi, Eduardoa,,b; Chamberlain, Samuel R.u,,v; Ioannidis, Konstantinosu,,v;
Rodriguez, Carolyn I.k,,w; Garg, Kabirb; Castle, Davidx; Van Ameringen,
Michaely,,z; Stein, Dan J.aa; Carmi, Liorbb,,cc; Zohar, Josephbb,,dd; Menchon,
Jose M.ee Clinical advances in obsessive-compulsive disorder: a position
statement by the International College of Obsessive-Compulsive Spectrum
Disorders, International Clinical Psychopharmacology: July 2020 - Volume 35 -
Issue 4 - p 173-193 doi: 10.1097/YIC.0000000000000314
217. Pallanti S. Importance of SARs-Cov-2 anosmia: From phenomenology to
neurobiology. Compr.Psychiatry.2020;100:152184.Doi:
10.1016/j.comppsych.2020.152184
218. Pallanti S, Grassi E, Makris N, Gasic GP, Hollander E. Neurocovid-19: A clinical
neuroscience-based approach to reduce SARS-CoV-2 related mental health
sequelae [published online ahead of print, 2020 Aug 15]. J Psychiatr Res.
2020;130:215-217. doi: 10.1016/j.jpsychires.2020.08.008

22. 219. Netto, V.D.M., Flores, C., Pallanti, S. Pharmacological Treatment for Comorbid
Bipolar Disorder and Obsessive-Compulsive Disorder in Adults, Journal of
Psychiatric Practice: September 2020 - Volume 26 - Issue 5 - p 383-393. doi:
10.1097/PRA.0000000000000499
220. Gaur S, Pallanti S. Treatment Outcomes in an Adult Attention Deficit Hyperactivity
Disorder Clinic with a Focus on Executive Functioning and Sluggish Cognitive
Tempo. Cureus 12(8): e9814. doi: 10.7759/cureus.9814
221. Pallanti, S., Porta, F., Salerno, L., Adult attention deficit hyperactivity disorder in
patients with fibromyalgia syndrome: Assessment and disabilities, Journal of
Psychiatric Research, 2020, ISSN 0022-3956,
https://doi.org/10.1016/j.jpsychires.2020.10.027.
(http://www.sciencedirect.com/science/article/pii/S002239562031030X)
222. Castro?Calvo, J., King, D. L., Stein, D. J., Brand, M., Carmi, L., Chamberlain, S. R.,
Demetrovics, Z., Fineberg, N. A., Rumpf, H.?J., Yücel, M., Achab, S., Ambekar, A.,
Bahar, N., Blaszczynski, A., Bowden?Jones, H., Carbonell, X., Chan, E. M. L., Ko,
C.?H., de Timary, P., Dufour, M., Grall?Bronnec, M., Lee, H. K., Higuchi, S.,
Jimenez?Murcia, S., Király, O., Kuss, D. J., Long, J., Müller, A., Pallanti, S.,
Potenza, M. N., Rahimi?Movaghar, A., Saunders, J. B., Schimmenti, A., Lee, S.?Y.,
Siste, K., Spritzer, D. T., Starcevic, V., Weinstein, A. M., Wölfling, K., and Billieux, J.
(2021) Expert appraisal of criteria for assessing gaming disorder: An international
Delphi study. Addiction, https://doi.org/10.1111/add.15411.
223. Correll, CU., Demyttenaere, K., Fagiolini, A., Hajak, G., Pallanti, S., Racagni, G.,
Singh, S. Future Neurology 2020 15:4. 30 Nov 2020 https://doi.org/10.2217/fnl-
2020-0012
224. Micheli, L, Spitoni, S, Di Cesare Mannelli, L, Bilia, AR, Ghelardini, C, Pallanti, S.
Bacopa monnieri as augmentation therapy in the treatment of anhedonia, preclinical
and clinical evaluation. Phytotherapy Research. 2020; 34: 2331- 2340.
https://doi.org/10.1002/ptr.6684
225. Fineberg, N. A., Van Ameringen, M., Drummond, L., Hollander, E., Stein, D. J.,
Geller, D., Walitza, S., Pallanti, S., Pellegrini, L., Zohar, J., Rodriguez, C. I.,
Menchon, J. M., Morgado, P., Mpavaenda, D., Fontenelle, L. F., Feusner, J. D.,
Grassi, G., Lochner, C., Veltman, D. J., Sireau, N., … Dell'Osso, B. (2020). How to
manage obsessive-compulsive disorder (OCD) under COVID-19: A clinician's guide
from the International College of Obsessive Compulsive Spectrum Disorders
(ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network
(OCRN) of the European College of Neuropsychopharmacology. Comprehensive
psychiatry, 100, 152174. https://doi.org/10.1016/j.comppsych.2020.152174
226. Uzunova, G., Pallanti, S., Hollander, E. (2021) Presentation and management of
anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection,
and in the post-COVID-19 recovery phase, International Journal of Psychiatry in
Clinical Practice, DOI: 10.1080/13651501.2021.1887264
227. Lolli F, Salimova M, Scarpino M, Lanzo G, Cossu C, Bastianelli M, Occupati B, Gori
F, Del Vecchio A, Ercolini A, Pascolo S, Cimino V, Meneghin N, Fierini F, D'Anna G,

23. Innocenti M, Ballerini A, Pallanti S, Grippo A, Mannaioni G. A randomised, double-
blind, sham-controlled study of left prefrontal cortex 15 Hz repetitive transcranial
magnetic stimulation in cocaine consumption and craving. PLoS One. 2021 Nov
16;16(11):e0259860. doi: 10.1371/journal.pone.0259860. PMID: 34784373.
228. Nezgovorova, V., Ferretti, CJ., Pallanti, S., Hollander, E. Modulating
neuroinflammation in COVID-19 patients with obsessive-compulsive disorder,
Journal of Psychiatric Research,2021, ISSN 0022-3956,
https://doi.org/10.1016/j.jpsychires.2021.11.025.
229. Pallanti, S., Marras, A., & Makris, N. (2021). A Research Domain Criteria Approach
to Gambling Disorder and Behavioral Addictions: Decision-Making, Response
Inhibition, and the Role of Cannabidiol. Frontiers in psychiatry, 12, 634418.
https://doi.org/10.3389/fpsyt.2021.634418
230. Castle D, Beilharz F, Phillips KA, Brakoulias V, Drummond LM, Hollander E,
Ioannidis K, Pallanti S, Chamberlain SR, Rossell SL, Veale D, Wilhelm S, Van
Ameringen M, Dell'Osso B, Menchon JM, Fineberg NA. Body dysmorphic disorder:
a treatment synthesis and consensus on behalf of the International College of
Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and
Related Disorders Network of the European College of Neuropsychopharmacology
(Pallanti, S.) Int Clin Psychopharmacol. 2021 Mar 1;36(2):61-75. doi:
10.1097/YIC.0000000000000342. PMID: 33230025; PMCID: PMC7846290.
231. Bentatti, B., Dell'Osso, B., Shen, H., Filippou-Frye, M., Varias, A., Sanchez, C., Jo,
Booil., Hollander, E., Fineberg, NA., Stein, DJ., Nicolini, H., Lanzagorta, N.,
Marazziti, D., Pallanti, S., Van Ameringen, M., Lochner, C., Karamustafalioglu, O.,
Hranov, L., Figee, M., Drummond, L., Grant, JE., Denys D., Fontenelle LF.,
Menchon JM., Zohar, J., Pellegrini, L., Rodriguez, C. Prevalence and correlates of
current suicide risk in an international sample of OCD adults: A report from the
International College of Obsessive-Compulsive Spectrum Disorders (ICOCS)
network and Obsessive Compulsive and Related Disorders Network (OCRN) of the
European College of Neuropsychopharmacology, Journal of Psychiatric Research,
Volume 140, 2021, Pages 357-363, ISSN 0022-3956,
https://doi.org/10.1016/j.jpsychires.2021.05.054.
232. Pallanti S. Neuromodulation; TMS (Transcranial Magnetic Stimulation) and the
other Non-Invasive Brain Stimulation (NIBS) in the era of brain connectivity,
European Neuropsychopharmacology, Elsevier, Editorial.
https://doi.org/10.1016/j.euroneuro.2021.03.004
233. Salerno L., Pallanti S. COVID-19 Related Distress in Gambling Disorder. Frontiers
in Psychiatry. VOLUME12. 2021. pp156.
https://www.frontiersin.org/article/10.3389/fpsyt.2021.620661.
DOI10.3389/fpsyt.2021.620661. ISSN1664-0640
234. Grassi, G., Figee, M., Stratta, P., Rossi, A., & Pallanti, S. Response to Cognitive
impulsivity and the behavioral addiction model of obsessive-compulsive disorder:
Abramovitch and McKay (2016), Journal of Behavioral Addictions J Behav Addict,
5(3), 398-400. Retrieved Apr 9, 2021, from
https://akjournals.com/view/journals/2006/5/3/article-p398.xml

24. 235. Pallanti S, Salerno L. ADHD: the dark side of Eating Disorders. Evidence-based
Psychiatric Care 2016;2;24-31, http:/ www.evidence-based-psychiatric-care.org/wp-
content/uploads/2016/07/05_pallanti.pdf. ISSN: 2421-4469
236. Benatti, B., Girone, N., Conti, D., Cafaro, R., Vigano, C., Briguglio, M., Marazziti, D.,
Mucci, F., Gambini, O., Demartini, B., Tundo, A., Necci, R., De Berardis, D.,
Galentino, R., De Michele, S., Balestrino, R., Albert U., Rogardetto S., Mania, G.,
Grassi, G., Pallanti, S., Amerio, A., Aguglia, A., Presta, D., Amore, M., Priori, A.,
Servello, D., Porta, M., Dell'Osso, B. (2021). Assessing response, remission and
treatment resistance in patients with Obsessive-Compulsive Disorder with and
without Tic Disorders: results from a multicenter study. CNS Spectrums, 1-22.
Doi:10.1017/S109285292100081X
237. Pallanti, S., Marras, A., Dickson, S. L., Adan, R. A. H., Vieta, E., Dell Osso, B.,
Arango, C., Fusar-Poli, P., Soriano-Mas, C., Carmi, L., Meyer Lindenberg, A., Zohar,
J. Manifesto for an ECNP Neuromodulation Thematic Working Group (TWG): Non-
invasive brain stimulation as a new Super-subspecialty, European
Neuropsychopharmacology, Volume 52, 2021, Pages 72-83, ISSN 0924-977X,
https://doi.org/10.1016/j.euroneuro.2021.07.002.
(https://www.sciencedirect.com/science/article/pii/S0924977X21002728)
238. Castle, D., Beilharz, F., Phillips, K. A., Brakoulias, V., Drummond, L. M., Hollander,
E., Ioannidis, K., Pallanti, S., Chamberlain, S. R., Rossell, S. L., Veale, D., Wilhelm,
S., Van Ameringen, M., Dell'Osso, B., Menchon, J. M., & Fineberg, N. A. (2021).
Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the
International College of Obsessive-Compulsive Spectrum Disorders and the
Obsessive Compulsive and Related Disorders Network of the European College of
Neuropsychopharmacology. International clinical psychopharmacology, 36(2), 61-
75. https://doi.org/10.1097/YIC.0000000000000342
239. Correll, CU., Demyttenaere, K., Fagiolini, A., Hajak, G., Pallanti, S., Racagni, G.,
Singh, S. Cariprazine in the management of negative symptoms of schizophrenia:
state of the art and future perspectives. Future Neurology 2020 15:4. 30 Nov 2020
https://doi.org/10.2217/fnl-2020-0012
240. Sforzini L, Worrell C, Kose M, Anderson IM, Aouizerate B, Arolt V, Bauer M, Baune
BT, Blier P, Cleare AJ, Cowen PJ, Dinan TG, Fagiolini A, Ferrier IN, Hegerl U,
Krystal AD, Leboyer M, McAllister-Williams RH, McIntyre RS, Meyer-Lindenberg A,
Miller AH, Nemeroff CB, Normann C, Nutt D, Pallanti S, Pani L, Penninx BWJH,
Schatzberg AF, Shelton RC, Yatham LN, Young AH, Zahn R, Aislaitner G, Butlen-
Ducuing F, Fletcher C, Haberkamp M, Laughren T, Mäntylä FL, Schruers K,
Thomson A, Arteaga-Henríquez G, Benedetti F, Cash-Gibson L, Chae WR, De
Smedt H, Gold SM, Hoogendijk WJG, Mondragón VJ, Maron E, Martynowicz J,
Melloni E, Otte C, Perez-Fuentes G, Poletti S, Schmidt ME, van de Ketterij E, Woo
K, Flossbach Y, Ramos-Quiroga JA, Savitz AJ, Pariante CM. A Delphi-method-
based consensus guideline for definition of treatment-resistant depression for
clinical trials. Mol Psychiatry. 2021 Dec 15. doi: 10.1038/s41380-021-01381-x. Epub
ahead of print. PMID: 34907394.
241. Castle, D., Beilharz, F., Phillips, K. A., Brakoulias, V., Drummond, L. M., Hollander,

25. E., Ioannidis, K., Pallanti, S., Chamberlain, S. R., Rossell, S. L., Veale, D., Wilhelm,
S., Van Ameringen, M., Dell'Osso, B., Menchon, J. M., & Fineberg, N. A. (2021).
Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the
International College of Obsessive-Compulsive Spectrum Disorders and the
Obsessive Compulsive and Related Disorders Network of the European College of
Neuropsychopharmacology. International clinical psychopharmacology, 36(2), 61-
75. https://doi.org/10.1097/YIC.0000000000000342
242. Pallanti S. Neuromodulation; TMS (Transcranial Magnetic Stimulation) and the
other Non Invasive Brain Stimulation (NIBS) in the era of brain connectivity. Eur
Neuropsychopharmacol. 2021 Apr;45 38. doi:10.1016/j.euroneuro.2021.03.004.
PMID: 33745763. Lolli F, Salimova M, Scarpino M, Lanzo G, Cossu C, Pallanti S.,
Mannaioni, G. et.al. (2021) A randomised, double-blind, sham-controlled study of
left prefrontal cortex 15 Hz repetitive transcranial magnetic stimulation in cocaine
consumption and craving. PLOS ONE 16(11): e0259860.
https://doi.org/10.1371/journal.pone.0259860
243. Benatti, B., Girone, N., Conti, D., Cafaro, R., Viganò, C., Briguglio, M., Pallanti S.,
Dell'Osso, B. et.al. (2021). Assessing response, remission, and treatment
resistance in patients with obsessive-compulsive disorder with and without tic
disorders: Results from a multicenter study. CNS Spectrums, 1-7.
doi:10.1017/S109285292100081X
244. Benatti, B., Dell'Osso, B., Shen, H., Filippou-Frye, M., Varias, A., Sanchez, Booil Jo,
C., Hollander, E., Fineberg, NA., Stein, DJ., Nicolini, H., Lanzagorta, N., Marazziti,
D., Pallanti, S., Van Ameringen, M., Lochner, C., Karamustafalioglu, O., Hranov, L.,
Figee, M., L., Drummond, Grant, JE., Denys, D., Fontenelle, LF., Menchon, JM.,
Zohar, J., Pellegrini, L., Rodriguez, CI. Prevalence and correlates of current suicide
risk in an international sample of OCD adults: A report from the International
College of Obsessive-Compulsive Spectrum Disorders (ICOCS) network and
Obsessive Compulsive and Related Disorders Network (OCRN) of the European
College of Neuropsychopharmacology, Journal of Psychiatric Research,Volume
140, 2021, Pages 357-363, ISSN 0022-3956,
https://doi.org/10.1016/j.jpsychires.2021.05.054.
245. Benatti, B., Ferrari, S., Grancini, B., Girone, N., Briguglio, M., Marazziti, D., Pallanti.
S., Dell'Osso, B. et.al. (2021). Suicidal ideation and suicidal attempts in patients
with obsessive-compulsive tic-related disorder vs obsessive-compulsive disorder:
Results of a multicenter Italian study. CNS Spectrums, 26(4), 354-361.
doi:10.1017/S1092852920001157
246. Pallanti, S., Makris, N., Camprodon, J., Rathi, Y., Salerno, L., Marras, A., & Gavazzi,
G. (2021). P. 0611 Theta burst stimulation of the pre-supplementary motor area in
gambling disorder: preliminary data on gambling severity and clinical global
impression. European Neuropsychopharmacology, 53, S449.
247. Van Ameringen, M., Patterson, B., Turna, J., Lethbridge, G., Bergmann, C. G.,
Lamberti, N., S Pallanti, G Grassi, M Vismara, Umberto Albert, R Gedanke Shavitt,
E Hollander, J Feusner, CI Rodriguez, Pedro Morgado Dell'Osso, B. (2022).
Obsessive-compulsive disorder during the COVID-19 pandemic. Journal of
Psychiatric Research.

26. 248. Benatti B, Girone N, Celebre L, Vismara M, Hollander E, Fineberg NA, Stein DJ,
Nicolini H, Lanzagorta N, Marazziti D, Pallanti S, van Ameringen M, Lochner C,
Karamustafalioglu O, Hranov L, Figee M, Drummond LM, Grant JE, Denys D,
Fontenelle LF, Menchon JM, Zohar J, Rodriguez CI, Dell'Osso B. The role of gender
in a large international OCD sample: A Report from the International College of
Obsessive-Compulsive Spectrum Disorders (ICOCS) Network. Compr Psychiatry.
2022 Apr 13;116:152315. doi: 10.1016/j.comppsych.2022.152315. Epub ahead of
print. PMID: 35483201.
249. Pallanti, S., Ponzio, M., Grassi, E., Vannini, G., Cauli, G. Transcranial
Photobiomodulation for the Treatment of Children with Autism Spectrum Disorder
(ASD): A Retrospective Study. Children 2022, 9, 755.
https://doi.org/10.3390/children9050755
250. Salerno, L., Grassi, E., Makris, N. et al. “A Theta Burst Stimulation on Pre-SMA:
Proof-of-Concept of Transcranial Magnetic Stimulation in Gambling Disorder”. J
Gambl Stud (2022). https://doi.org/10.1007/s10899-022-10129-3
251. Borwin Bandelow, Christer Allgulander, David S. Baldwin, Daniel Lucas da
Conceição Costa, Damiaan Denys, Nesrin Dilbaz, Katharina Domschke, Elias
Eriksson, Naomi A. Fineberg, Josef Hättenschwiler, Eric Hollander, Hisanobu Kaiya,
Tatiana Karavaeva, Siegfried Kasper, Martin Katzman, Yong-Ku Kim, Takeshi Inoue,
Leslie Lim, Vasilios Masdrakis, José M. Menchón, Euripedes C. Miguel, Hans-
Jürgen Möller, Antonio E. Nardi, Stefano Pallanti, Giampaolo Perna, Dan Rujescu,
Vladan Starcevic, Dan J. Stein, Shih-Jen Tsai, Michael Van Ameringen, Anna
Vasileva, Zhen Wang & Joseph Zohar (2022) World Federation of Societies of
Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-
compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety
disorders, The World Journal of Biological
Psychiatry, DOI: 10.1080/15622975.2022.2086295
252. Ilenia Pampaloni, Sabina Marriott, Enrico Pessina, Claire Fisher, Anusha Govender,
Heba Mohammed, Augusta Chandler, Himanshu Tyagi, Lucy Morris, Stefano
Pallanti, The global assessment of OCD, Comprehensive Psychiatry, 2022,
152342, ISSN 0010-440X,
https://doi.org/10.1016/j.comppsych.2022.152342.(https://www.sciencedirect.com/s
cience/article/pii/S0010440X22000487)